Skip to main content
Top
Published in: Annals of Nuclear Medicine 3/2010

01-04-2010 | Original Article

Associations between liver 18F fluoro-2-deoxy-d-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome

Authors: Kiyohisa Kamimura, Shigeki Nagamachi, Hideyuki Wakamatsu, Ryutaro Higashi, Mikio Ogita, Shin-ichiro Ueno, Seigo Fujita, Yoshiro Umemura, Toshiro Fujimoto, Masayuki Nakajo

Published in: Annals of Nuclear Medicine | Issue 3/2010

Login to get access

Abstract

Purpose

Liver demonstrates a heterogeneous 18F fluoro-2-deoxy-d-glucose (18F-FDG) uptake pattern and sometimes shows an abnormally increased uptake even when there is no malignant tissue. The aim of this study was to evaluate the relationships of liver 18F-FDG uptake as related to physical factors, fatty liver, blood glucose (BG), and other biochemical data.

Methods

18F-FDG positron emission tomography (PET) imaging was performed in 101 consecutive subjects for cancer screening. Multiple stepwise regression analysis was used to define the best predictors of the liver standardized uptake value (SUV) among height, weight, waist circumference, body mass index (BMI), systolic and diastolic blood pressure, BG and other biochemical data, i.e., aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, total cholesterol, high-density lipoprotein cholesterol, triglycerides, total protein, total bilirubin, and alkaline phosphatase. Furthermore, we evaluated the association between liver 18F-FDG uptake and the metabolic syndrome.

Results

The independent factors for increased liver 18F-FDG uptake (mean SUV >= 2) were BMI (P < 0.0001), triglycerides (P = 0.0007), and high-density lipoprotein cholesterol (P = 0.0013). Other factors were not significantly associated with liver 18F-FDG uptake. In addition, the liver 18F-FDG uptake of metabolic syndrome subjects was significantly higher than that of a non-metabolic syndrome subjects.

Conclusions

BMI was the strongest determinant of liver 18F-FDG uptake, and the liver 18F-FDG uptake of metabolic syndrome subjects was significantly higher than that of non-metabolic syndrome subjects. This result suggests that a subject with a high liver 18F-FDG uptake should be screened for the metabolic syndrome.
Literature
1.
go back to reference Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308–14.CrossRefPubMed Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308–14.CrossRefPubMed
2.
go back to reference Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185–91.CrossRefPubMed Ichiya Y, Kuwabara Y, Sasaki M, Yoshida T, Akashi Y, Murayama S, et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med. 1996;10:185–91.CrossRefPubMed
3.
go back to reference Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143.
4.
go back to reference Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004;2:383–7.CrossRef Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004;2:383–7.CrossRef
5.
go back to reference The Examination Committee of Criteria for Metabolic Syndrome. The definition and criteria of metabolic syndrome. J Jpn Soc Int Med. 2005;94:794–809. The Examination Committee of Criteria for Metabolic Syndrome. The definition and criteria of metabolic syndrome. J Jpn Soc Int Med. 2005;94:794–809.
6.
go back to reference Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847–50.PubMed Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847–50.PubMed
7.
go back to reference Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. 2000;14:121–6.CrossRefPubMed Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. 2000;14:121–6.CrossRefPubMed
8.
go back to reference Tan LT, Ong KL. Semi-quantitative measurements of normal organs with variable metabolic activity on FDG PET imaging. Ann Acad Med Singapore. 2004;33:183–5.PubMed Tan LT, Ong KL. Semi-quantitative measurements of normal organs with variable metabolic activity on FDG PET imaging. Ann Acad Med Singapore. 2004;33:183–5.PubMed
9.
go back to reference Smith SR, Ravussin E. Emerging paradigms for understanding fatness and diabetes risk. Curr Diab Rep. 2002;2:223–30.CrossRefPubMed Smith SR, Ravussin E. Emerging paradigms for understanding fatness and diabetes risk. Curr Diab Rep. 2002;2:223–30.CrossRefPubMed
11.
go back to reference Brass EP, Vetter WH. Interleukin-6, but not tumour necrosis factor-alpha, increases lipogenesis in rat hepatocyte primary cultures. Biochem J. 1994;301:193–7.PubMed Brass EP, Vetter WH. Interleukin-6, but not tumour necrosis factor-alpha, increases lipogenesis in rat hepatocyte primary cultures. Biochem J. 1994;301:193–7.PubMed
12.
go back to reference West J, Morton DJ, Esmann V, Stjernholm RL. Carbohydrate metabolism in leukocytes. 8. Metabolic activities of the macrophage. Arch Biochem Biophys. 1968;124:85–90.CrossRefPubMed West J, Morton DJ, Esmann V, Stjernholm RL. Carbohydrate metabolism in leukocytes. 8. Metabolic activities of the macrophage. Arch Biochem Biophys. 1968;124:85–90.CrossRefPubMed
13.
go back to reference Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–80.PubMed Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–80.PubMed
14.
go back to reference Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–9.PubMed Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–9.PubMed
15.
go back to reference Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14:185–92.CrossRefPubMed Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14:185–92.CrossRefPubMed
16.
go back to reference Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–72.CrossRefPubMed Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–72.CrossRefPubMed
Metadata
Title
Associations between liver 18F fluoro-2-deoxy-d-glucose accumulation and various clinical parameters in a Japanese population: influence of the metabolic syndrome
Authors
Kiyohisa Kamimura
Shigeki Nagamachi
Hideyuki Wakamatsu
Ryutaro Higashi
Mikio Ogita
Shin-ichiro Ueno
Seigo Fujita
Yoshiro Umemura
Toshiro Fujimoto
Masayuki Nakajo
Publication date
01-04-2010
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 3/2010
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-009-0338-1

Other articles of this Issue 3/2010

Annals of Nuclear Medicine 3/2010 Go to the issue